Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.47 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDA | P32320 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198406 | 1.00 | PYGM (0.53) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1071873 | 0.90 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1071869 | 0.90 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18740738 | 0.90 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL157986 | 0.88 | PYGM (0.65) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL157985 | 0.88 | PYGM (0.65) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL11883660 | 0.88 | PYGM (0.57) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL30130603 | 0.87 | PYGM (0.56) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL11877280 | 0.87 | PYGM (0.56) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15810617 | 0.87 | PYGM (0.49) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| CN-117750971-A | Methods of treating or preventing autoimmune diseases | 易姆赛斯股份公司 | 2024-03-22 | — | — | CN | claimed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612658-B2 | RNA replication using transcription polymerases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12582609-B2 | Cancer vaccines | MODERNATX, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260071212-A1 | GalNAc conjugated oligonucleotides for RNA editing | KORRO BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071215-A1 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3752610-B1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2026-01-28 | — | — | EP | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-5476931-A | Reacting with a base in a mixed solvent containing alcohol | RIKAGAKU KENKYUSHO (JP) | 1995-12-19 | — | — | US | disclosed |
| EP-0311694-B1 | NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | RIKAGAKU KENKYUSHO (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-5144018-A | Antiviral Agents | RIKAGAKU KENKYUSHO (JP) | 1992-09-01 | — | — | US | disclosed |
| EP-0311694-A1 | NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | RIKAGAKU KENKYUSHO (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582609-B2 | Cancer vaccines | RNMT, MICA, NSUN2 | PYGM 4875/4885SLC28A1 2511/4885SLC28A2 2534/4885 |
| US-20260071215-A1 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | UPF1, RBM26, RPRD2 | PYGM 2646/4885SLC28A1 377/4885SLC28A2 212/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | PYGM 3599/4885SLC28A1 1985/4885SLC28A2 1854/4885 |
| US-12612658-B2 | RNA replication using transcription polymerases | RNGTT, POLRMT, POLM | PYGM 1875/4885SLC28A1 3216/4885SLC28A2 2858/4885 |
| US-20260071212-A1 | GalNAc conjugated oligonucleotides for RNA editing | NSUN3, ADAR, TRMT1L | PYGM 454/4885SLC28A1 386/4885SLC28A2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.